The present study was undertaken to evaluate the extent to which an endogenous interleukin-1 (IL-1) response contributes to the hemodynamic and metabolic consequences of sublethal endotoxemia or lethal Gram-negative septic shock. Young, healthy baboons received either a sublethal dose oflipopolysaccharide (LPS) or an LDIoo of live Escherichia coli bacteria, and one half of the animals in each group were continuously infused with IL-1 receptor antagonist (IL-ira). Plasma IL-/1# was not detected in this model of endotoxemia. Administration of ILira had only minimal effects on the modest hemodynamic and metabolic responses to sublethal endotoxemia, and did not attenuate the plasma cytokine response. In contrast, high circulating levels of IL-1iB (range 300800 pg/ml) were seen during lethal E. coli septic shock. IL-ira treatment significantly attenuated the decrease in mean arterial blood pressure (MAP) (from -72±8 to -43±6 mm Hg, P < 0.05) and cardiac output (from -0.81±0.17 to -0.48±0.15 liter/min; P < 0.05), and significantly improved survival from 43 to 100% at 24 h (P < 0.05). The plasma I-i1d and IL-6 responses to lethal E. coli septic shock were also significantly diminished by IL-ira treatment (P < 0.05), whereas tumor necrosis factor-a (TNFa) concentrations were unaffected. We conclude that an exaggerated systemic IL-1,6 response is characteristic of lethal E. coli septic shock, and contributes significantly to the hemodynamic and metabolic consequences of E. coli septic shock. IL-ira can significantly attenuate the cytokine cascade and improve survival. (J. Clin. Invest. 1992. 89:1551-1557.) Key words: tumor necrosis factor * interleukin-6 * interleukin-8 * lipopolysaccharide
Introduction
IL-1 is a pleiotropic cytokine presumed to participate in the initiation and regulation of the acute-phase response to injury and infection (1) . Endogenous IL-I production contributes to the febrile and hepatic acute-phase protein responses, as well as to the anorexia and skeletal protein wasting seen during an acute inflammatory response (2, 3) .
Earlier investigations of the cytokine cascade initiated during Gram-negative septic shock have emphasized a proximal role for tumor necrosis factor-a (TNFa).' Administration of TNFa to otherwise healthy animals induces cardiovascular collapse, multiorgan system failure, and death, similar to that seen in experimental lethal endotoxemia and in clinical sepsis (4) . Passive immunization of primates with antibodies to TNFa improves survival in E. coli septic shock (5) . However, an increasing body ofevidence has also accumulated to suggest a role for IL-I in the pathogenesis of Gram-negative septic shock.
We have recently reported that administration of recombinant human IL-la to healthy primates will result in hypotension and tachycardia similar to that seen in endotoxemia (6) . Although quantities as low as 100 ng/kg body weight (BW) will produce significant tachycardia, 100 gg/kg BW of IL-la decreases cardiac output and causes adrenal cortex hemorrhage. Okusawa and Dinarello also reported that administration of IL-lI# to rabbits induced hypotension, decreased systemic vascular resistance, and central venous pressures, as well as increased heart rate and cardiac output (7) . Furthermore, IL-I( potentiated the deleterious effects ofTNFa (7, 8) . OhIsson and colleagues have recently reported that an endogenous IL-1 response contributes to endotoxin-induced lethality, as treatment ofrabbits with a newly described IL-l receptor antagonist (IL-lra) improves survival (9) . Similarly, Wakabayashi and Dinarello have observed that treatment of rabbits with IL-lra blunts hypotension in sublethal E. coli shock (10) .
The present study was designed to examine the role of endogenously produced IL-I in the hemodynamic and metabolic responses to a mild endotoxemia and to a lethal Gram-negative bacterial (E. cola) infection in nonhuman primates. To inhibit the actions ofendogenously produced IL-l, IL-lra was administered continuously during the course of mild endotoxemia and in lethal E. coli septic shock. A primate model of sublethal endotoxemia and lethal septic shock was chosen for several reasons. First, this E. coli septic shock model is well controlled, reproducible, and manifests many of the clinical responses seen in decompensated septic shock, such as a transient increase and subsequent decrease in cardiac output, hypotension, and tachycardia. Although the animals are provided crystalloid resuscitation, inotropic agents or ventilatory support are not employed. Second, similarities between human and Papio cytokines allow a full characterization ofthe cytokine response in sepsis. Antibodies against human IL-1j, TNFa, IL-8, and IL-Ira all crossreact with the corresponding Papio mediators, but do not crossreact with either mouse or rabbit proteins. Third, the pharmacokinetics of human recombinant IL-Ira in baboons would be expected to more closely approximate those in humans. Finally, this E. coli septic shock model has been used to explore the role ofTNFa (5), allowing a direct comparison between the role of these two mediators.
In order to obtain a controlled and reproducible experimental septic shock model, a single bolus infusion of lethal quantities of E. coli was employed. However, this model differs from the pathogenesis of clinical septic shock which often originates from a nidus of infection. Furthermore, the interpretation of the results may be confounded to some degree as they are evaluated while the animal is in an anesthesized state, even though anesthetized control animals in previous studies have shown no significant hemodynamic changes (6) .
The IL-I ra employed in the present study is a 1 7-kD recombinant human protein that shares 26% sequence homology with IL-I13, binds to the IL-l type I receptor with equal affinity, but has no agonist activity (1 1) . When administered at a 1,000-M excess, IL-Ira will block the hemodynamic and metabolic responses produced by IL-l a administration (6) .
Methods
Reagents. IL-Ira was produced at Synergen Inc. Before intravenous administration, the IL-Ira was diluted with physiologic saline (0.9% sodium chloride; 0.5 ml/kg [BW] (12, 13) . The sensitivity of the assays are 30 and 34 pg/ml, respectively. Plasma IL-8, a recently described cytokine with neutrophil chemotactic properties, was also measured by ELISA with a sensitivity of 80 pg/ml (14) . An ELISA was used to determine IL-Ira concentrations. A polyclonal rabbit antibody raised against recombinant human IL-lra and purified by affinity chromatography was employed as the capture antibody. The affinity-purified antibody was also biotinylated, and a horse radish peroxidase conjugatedto avidin was used to visualize the captured protein.
The lower limit of detection for this assay is 600 pg/ml. IL-6 activity was determined using the B.9 hybridoma cell proliferation assay (15) . One unit of activity is defined as the quantity of IL-6 required to produce half-maximal proliferation (lower limit ofdetection 10 B.9 U/ml).
Plasnia glucose was measured using an automated glucose oxidase analyzer (Glucose Analyzer 2; Beckman Instruments Inc., Sunnyvale, CA Statistical analyses. Data were analyzed with a microcomputerbased commercial statistical package (StatPac®; Northwest Analytical, Portland, OR). Changes in hemodynamic, hematologic, and hormonal/metabolic responses due to time, and the individual treatment regimens were analyzed by one-and two-way analysis ofvariance. Comparisons between groups were performed using Newman-Keuls' multiple range test. Statistical significance was designated at the 95% confidence level.
Results
Sublethal endotoxemia. Baboons receiving 500 ,ug/kg BW of Salmonella typhosa LPS showed only a 17% decrease in MAP, and a 44% increase in heart rate (both P < 0.05). Pulmonary capillary wedge pressures (PCWP) also declined (data not shown), whereas cardiac output was unaffected. IL-1ra treatment had no significant effect on changes in tachycardia, cardiac output, and MAP produced by this mild degree of endotoxemia (Fig. 1) .
LPS induced a systemic TNFa and IL-6 response that were unaffected by IL-lra treatment (Fig. 2) . IL-8 levels were also unchanged by IL-I ra treatment. IL-1I3 was only randomly detected in the plasma in either group at a sensitivity of 30 pg/ml.
After endotoxin administration, total leukocyte numbers declined, reaching a nadir at 2 h (Fig. 3) , and rose again so that total leukocyte numbers were normal at 8 h. IL-1 ra administration did not prevent the leukopenia or subsequent leukocytosis that developed after endotoxemia. Platelet counts, fibrinogen concentrations, and fibrin split products were unaffected by this degree of endotoxemia (data not shown) in all animals.
Arterial blood glucose and lactate levels (data not shown) increased in all endotoxin-treated baboons (P < 0.05), and the changes were unaffected by IL-1ra teatment. (Fig. 4) . Fluid resuscitation was provided when the animals met predetermined criteria. As a result, crystalloid support during resuscitation tended to be lower in IL-lra-treated baboons than in placebo-treated controls (771±259 vs 1539±556 ml). However, as shown in Fig. 5 test vs placebo-treated baboons); however one of the IL-1 ratreated animals was anuric and had an elevated serum creatinine (3.5 mg/ml vs < 1.0 mg/ml at baseline).
Animal (Fig. 6) ; IL-lra infusions had no effect on these levels. In contrast, IL-I3 appeared in the circulation within 2 h and remained elevated for the entire 24 h, and these concentrations were significantly reduced in the IL-lra-treated baboons, compared with their sham-treated counterparts. IL-6 and IL-8 were also detectable Time. h, Figure 5 . (11, 16) . served after E. coli administration and IL-1ra treatment were the preservation of cardiac output and MAP. During endotoxin-induced shock in rabbits, Ohlsson and colleagues were ad remained elevated throughout the 24-h study also able to demonstrate reduced lethality and significantly de-[L-6 levels were reduced, but the IL-8 levels were creased tissue damage when animals were treated with IL-1 ra ( IL-lra treatment. (9) . In the present study, the improvement in outcome with icose decreased transiently in E. coli septic ba-IL-1 receptor blockade occurred despite the absence of any te levels increased continuously over the study significant attenuation in plasma TNFa levels. The present iing 44±18 mg/dl, approximately two times that findings demonstrate that endogenous TNFa production can [hal endotoxemia. IL-l ra treatment had no signifi-not by itself explain the pathophysiologic consequences of the lacticacidemia (Table I) . However, IL-lra lethal E. coli septic shock. Rather, they suggest that IL-1, or gnificantly minimized the nadir hypoglycemia mediators induced by IL-1, contribute significantly to this toxlethal E. coli septic shock (nadir 48±4 vs 62±6 icity. However, in earlier primate studies, exogenous IL-1 was 0.05). The other parameters were unaffected by unable to produce irreversible shock and widespread tissue I).
damage (6) , arguing that endogenous IL-1 by itself cannot exite blood cell numbers declined inE. coli septic plain the lethal effects of Gram-negative or endotoxemic remained suppressed over the course of the study shock. Rather, the data imply that IL-1 contributes to and pora treatment had no effect on the leukopenia. In tentiates TNFa-induced cardiovascular collapse.
and treatment groups, the leukopenia was asso-IL-1 ra administration significantly decreased the plasma (Table   Total whi animals and (Fig. 3) . IL-l both control (10) , the authors were unable to demonstrate a significant IL-1I3 decline in IL-Ira-treated animals. The discrepancy may be explained by differences in the severity of the two E. coli septic shock models. In both studies, the early hemodynamic changes are similar and most likely due to the direct effect of the injurious stimulus, as well as mediated by TNFa. Mortality in the Wakabayashi study was 40% after administration of killed E. coli bacteria; with the present model, early mortality was 57% after infusion of live E. coli, and long-term mortality approached 75%. Furthermore, the magnitude ofthe IL-113 response was markedly higher in the present study. In untreated E. coli septic baboons, the IL-11 response lasted 24 h, whereas in rabbit studies, the IL-113 response had returned to baseline within 5 h (10). In the present investigation, IL-Ira treatment did not block the initial production of IL-13, but prevented a sustained response. This initial spike in IL-13 refractory to IL-Ira treatment is likely the direct result of E. coli bacteremia, endotoxemia, and the subsequent endogenous TNFa response, all of which can induce IL-1 production (20) . The resulting decline in IL-11 levels may be explained by ILIra inhibition of IL-113 synthesis, as in vitro studies have shown that IL-113 can induce IL-113 gene transcription in an autocrine manner (2 1).
The differences in severity between this and the rabbit model of Wakabayashi can also explain the failure of IL-1 ra to attenuate the leukopenia observed in the present study. In rabbits receiving sublethal E. coli infections, total white cell numbers declined by only 60%, and IL-Ira treatment attenuated this response by 30% (10) . In the present study, E. coli septic shock produced greater than 90% reduction in circulating white cell numbers, and the numbers were unaffected by IL-I ra treatment.
In comparison to E. coli shock, IL-Ira treatment had only minimal effects on the hemodynamic, substrate, and white cell responses to a sublethal endotoxemia. The absence of a systemic response to IL-Ira during sublethal endotoxemia was surprising and unanticipated. Whereas IL-1 ra treatment attenuated the hemodynamic changes and the plasma IL-6 response in lethal E. coli septic shock, it had no apparent effect during endotoxemia, suggesting that these responses to sublethal endotoxin administration are relatively IL-I independent. The failure of IL-Ira to block the hypotension and IL-6 responses during endotoxemia cannot be easily explained by an inability of the receptor antagonist to block IL-I mediated responses. It is unlikely that preservation of these responses can be explained by IL-I's actions on the type II receptor, as previous baboon studies have shown that IL-I receptor antagonist will block the hypotension and IL-6 responses to exogenous IL-Ia administration (6) .
Controversy exists whether a systemic IL-I response occurs at all during sublethal endotoxemia. Previous studies from this laboratory have failed to show a circulating plasma IL-11 response to endotoxemia in human volunteers (22 (23) . The present results would suggest that circulating IL-I is not likely to occur, or responsible for, most ofthe hemodynamic changes observed in sublethal endotoxemia.
In contrast, the severity of the infectious stimulus in the septic shock model correlates with the magnitude of the exaggerated IL-I response, and hence its detection in the circulation. Therefore, we conclude that IL-1 is not the principal mediator of the hemodynamic and pathophysiologic responses to sublethal endotoxemia. However, excessive IL-1 production contributes to the pathophysiologic responses to lethal E. coli infection. Furthermore, IL-1 receptor antagonist may be beneficial in the treatment ofhospitalized patients at risk ofdeveloping septic shock.
